BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 10220523)

  • 1. A comparison of budesonide and mesalamine for active Crohn's disease.
    Lowry PW; Sandborn WJ
    Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
    Bischoff A
    MMW Fortschr Med; 2010 Jan; 152(1-2):20. PubMed ID: 20302159
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acute episode].
    Schölmerich J;
    Z Gastroenterol; 2003 Jan; 41(1):27-30. PubMed ID: 12541170
    [No Abstract]   [Full Text] [Related]  

  • 6. [New research results give hope. Causal therapy of Crohn disease in sight].
    MMW Fortschr Med; 2004 Apr; 146(14):42-3. PubMed ID: 15344754
    [No Abstract]   [Full Text] [Related]  

  • 7. [Paradigmatic shift in drug treatment of Crohn disease].
    Munck LK
    Ugeskr Laeger; 2005 Aug; 167(33):3013. PubMed ID: 16109239
    [No Abstract]   [Full Text] [Related]  

  • 8. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
    Rutgeerts P
    Gut; 1999 Jul; 45(1):13-4. PubMed ID: 10498451
    [No Abstract]   [Full Text] [Related]  

  • 9. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Maintaining a remission].
    Fleig WE;
    Z Gastroenterol; 2003 Jan; 41(1):36-42. PubMed ID: 12541172
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug therapy of Crohn disease].
    Niemelä S
    Duodecim; 2001; 117(8):807-14. PubMed ID: 12116446
    [No Abstract]   [Full Text] [Related]  

  • 12. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
    Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
    Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional treatment of Crohn's disease: objectives and outcomes.
    Rutgeerts PJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S2-8. PubMed ID: 11380039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
    Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
    Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New therapeutic modalities in Crohn's disease].
    Rachmilewitz D
    Harefuah; 1999 Jun; 136(12):943-5. PubMed ID: 10955155
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Crohn's disease at the turn of the century.
    Bickston SJ; Cominelli F
    N Engl J Med; 1998 Aug; 339(6):401-2. PubMed ID: 9691110
    [No Abstract]   [Full Text] [Related]  

  • 19. The effectiveness of budesonide therapy for Crohn's disease.
    Kane SV; Schoenfeld P; Sandborn WJ; Tremaine W; Hofer T; Feagan BG
    Aliment Pharmacol Ther; 2002 Aug; 16(8):1509-17. PubMed ID: 12182751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
    MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.